Structure-based inhibitors of amyloid beta core suggest a common interface with tau

Sarah L. Griner(Howard Hughes Medical Institute), Paul M. Seidler(Howard Hughes Medical Institute), Jeannette T. Bowler(Howard Hughes Medical Institute), Kevin A. Murray(Howard Hughes Medical Institute), Tianxiao Yang(Howard Hughes Medical Institute), Shruti Sahay(Howard Hughes Medical Institute), M.R. Sawaya(Howard Hughes Medical Institute), Duilio Cascio(Howard Hughes Medical Institute), José A. Rodríguez(Howard Hughes Medical Institute), Stephan Philipp(University of California, Irvine), Justyna Sosna(University of California, Irvine), Charles Glabe(King Abdulaziz University), Tamir Gonen(Howard Hughes Medical Institute), David Eisenberg(Howard Hughes Medical Institute)
eLife
October 14, 2019
Cited by 116Open Access
Full Text

Abstract

Alzheimer's disease (AD) pathology is characterized by plaques of amyloid beta (Aβ) and neurofibrillary tangles of tau. Aβ aggregation is thought to occur at early stages of the disease, and ultimately gives way to the formation of tau tangles which track with cognitive decline in humans. Here, we report the crystal structure of an Aβ core segment determined by MicroED and in it, note characteristics of both fibrillar and oligomeric structure. Using this structure, we designed peptide-based inhibitors that reduce Aβ aggregation and toxicity of already-aggregated species. Unexpectedly, we also found that these inhibitors reduce the efficiency of Aβ-mediated tau aggregation, and moreover reduce aggregation and self-seeding of tau fibrils. The ability of these inhibitors to interfere with both Aβ and tau seeds suggests these fibrils share a common epitope, and supports the hypothesis that cross-seeding is one mechanism by which amyloid is linked to tau aggregation and could promote cognitive decline.


Related Papers

No related papers found

Powered by citation graph analysis